Director/PDMR Dealings

RNS Number : 1215H

Futura Medical PLC

13 November 2018

 

Director/PDMR Dealings

13 November 2018

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that certain of its Directors acquired new shares in the Company as part of the Fundraising announced on 19 October 2018 as detailed below.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	James Barder
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 7 pence per       Ordinary Share 357,142 Ordinary Shares
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	13 November 2018
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Angela Hildreth
2	Reason for the notification
a)	Position/status	Finance Director and Chief Operating Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 7 pence per    Ordinary Share 142,857 Ordinary Shares
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	13 November 2018
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ken James
2	Reason for the notification
a)	Position/status	Executive Director and Head of R&D
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 7 pence per   Ordinary Share 285,714 Ordinary Shares
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	13 November 2018
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Jonathan Freeman
2	Reason for the notification
a)	Position/status	Senior Independent Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 7 pence per    Ordinary Share 7,478     Ordinary Shares
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	13 November 2018
f)	Place of the transaction	London Stock Exchange, AIM

ENDS

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]

Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)

Tom Salvesen/ Mia Gardner (Corporate Broking)
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [e-mail]

Tel: [phone]

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

END

 

 

DSHBTBTTMBTBTAP